NCT07799090已完成1 期
Pilot Pharmacokinetic Study of GB-5001A 280 mg Long Acting Injection, in Comparison With the Comparator Drug Aricept® 5 mg and Aricept® 10 mg Film-coated Tablet in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- G2GBio, Inc.
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Pharmacokinetic parameter
研究概览
简要总结
This study is to find out whether the bioavailability of GB-5001A 280 mg Injection is compared to the comparator drug of Aricept® 5 mg and Aricept® 10 mg which are Film-Coated Tablet when administered in healthy subjects. Also to monitor the adverse events and to ensure the safety of the subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Able to participate, communicate well with the investigators and willing to provide written informed consent to participate in the study.
- •Healthy male subjects with absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluation, medical history or physical examination during the screening and could be considered healthy based on the evaluation.
- •Aged 19-45 years inclusive.
- •Non-smokers.
- •Body mass index within 18.5 to 30.0 kg/m
- •Vital signs (after 10 minutes rest) must be within the range (i.e Systolic blood pressure 100 - 129 mmHg; Diastolic blood pressure 60 - 84 mmHg)
- •Willing to practice abstention or non-hormonal contraception during the study.
排除标准
- •History of allergy or hypersensitivity or contraindication to Donepezil or other allied drugs.
- •Any major illness in the past 90 days or clinically significant ongoing chronic medical illness.
- •Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver function test (AST, ALT, alkaline phosphatase, total bilirubin, direct bilirubin ≥ 1.5 ULN), renal failure or renal function test (serum creatinine concentration > 1.4 mg/dL and ureum ≥ 1.5 ULN), etc.
- •Positive Hepatitis B surface antigen (HBsAg), anti-HCV, or anti-HIV.
- •Clinically significant hematology abnormalities.
- •Clinically significant 12-Lead electrocardiogram (12-Lead ECG) abnormalities.
- •Any surgical or medical condition (present or history) which might significantly alter the absorption, distribution, metabolism or excretion of the study drug, e.g. gastrointestinal disease including gastric or duodenal ulcers or history of gastric surgery.
- •Past history of anaphylaxis or angioedema.
- •History of drug or alcohol abuse within 12 months prior to screening for this study.
- •Participation in any clinical trial within the past 90 days calculated from the last visit until this study's first dosing day.
- •History of any bleeding or coagulative disorders.
- •Presence of difficulty in accessibility of veins in left or right arm.
- •A donation or significant blood loss within 90 days before this study's first dosing day.
- •Intake of any prescription drug (especially Donepezil), non prescription drug (including hormonal contraception), food supplements or herbal medicines within 28 days of this study's first dosing day.
- •History of allergic contact dermatitis.
- •History of muscle weakness.
- •History of myasthenia gravis.
- •History of peptic ulcer or Gastritis.
- •History of seizure.
- •History of bronchitis, asthma, or lung infections.
- •Bradycardia was detected during the screening process.
- •Difficulty in swallowing capsule or tablet.
研究组 & 干预措施
GB-5001A
Experimental
GB-5001A 280 mg long acting Injection
干预措施: GB-5001A 280 mg long acting Injection (Drug)
Aricept & GB-5001A
Experimental
Active Comparator: Aricept® 5 mg tablet and Experimental: GB 5001A 280 mg long acting Injection
干预措施: GB-5001A 280 mg long acting Injection (Drug)
Aricept & GB-5001A
Experimental
Active Comparator: Aricept® 5 mg tablet and Experimental: GB 5001A 280 mg long acting Injection
干预措施: Aricept® 5 mg film-coated tablet (Drug)
Aricept
Active Comparator
Aricept® 5 mg tablet and Aricept® 10 mg tablet
干预措施: Aricept® 5 mg film-coated tablet (Drug)
Aricept
Active Comparator
Aricept® 5 mg tablet and Aricept® 10 mg tablet
干预措施: Aricept® 10 mg film-coated tablet (Drug)
结局指标
主要结局
Pharmacokinetic parameter
时间窗: 204 days of G1, 226 days of G2, 40 days of G3
Peak plasma concentration during steady state (Cmax,ss)
次要结局
- Adverse events(Day 1 to Day 226)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Pharmacokinetics, Pharmacodynamics, and Safety study of TOL3022 in Patients with Advanced Prostate CancerCTRI/2025/11/098006Tolmar, Inc,48
招募中
不适用
A Double Blind Balanced Randomized Single Dose Two Treatment Two Sequence Two Period Two Way Crossover Oral Bioavailability Study Comparing Curcumin 1000 mg Hard CapsuleCTRI/2024/11/077316Cocrystal Health Industry Zhejiang Co Ltd12
已完成
1 期
Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy VolunteersNCT07587008AbbVie12
已完成
1 期
一项评估健康成年受试者单次皮下注射 GB08 注射液后的耐受性和安全性的 I 期临床试验儿童生长激素缺乏症CTR20241992深圳科兴药业有限公司
Unknown
1 期
一项双盲、单剂量、剂量递增、安慰剂对照，合并开放、阳性对照、平行试验评估健康成年受试者单次皮下注射递增剂量的 GB08 注射液后的耐受性和安全性的 I 期临床试验ChiCTR2400090912深圳科兴药业有限公司